0001140361-16-047651.txt : 20160112
0001140361-16-047651.hdr.sgml : 20160112
20160112173845
ACCESSION NUMBER: 0001140361-16-047651
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160111
FILED AS OF DATE: 20160112
DATE AS OF CHANGE: 20160112
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001302573
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383572512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-995-8200
MAIL ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dupont Jakob
CENTRAL INDEX KEY: 0001553335
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35993
FILM NUMBER: 161339549
MAIL ADDRESS:
STREET 1: C/O ONCOMED PHARMACEUTICALS, INC.
STREET 2: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc1.xml
FORM 4
X0306
4
2016-01-11
0
0001302573
OncoMed Pharmaceuticals Inc
OMED
0001553335
Dupont Jakob
C/O ONCOMED PHARMACEUTICALS, INC.
800 CHESAPEAKE DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
SVP & Chief Medical Officer
Common Stock
2016-01-11
4
M
0
2500
4.56
A
23142
D
Common Stock
2016-01-11
4
S
0
2500
20.0084
D
20642
D
Stock Option (Right to Buy)
4.56
2016-01-11
4
M
0
2500
0.00
D
2021-10-24
Common Stock
2500
138937
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 5, 2015.
Includes 15,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
This transaction was executed in multiple trades in prices ranging from $20.00 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option was immediately exercisable in full on October 24, 2011; however, the shares vest pursuant to the following schedule: Twenty Percent (20%) of the shares subject to the option vest on the first anniversary measured from October 1, 2011 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 48 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/ Alicia J. Hager, Attorney-in-Fact for Jakob Dupont
2016-01-12